ClinicalTrials.gg
CompletedNCT06597344SISUpdated Feb 11, 2026Results posted

A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

A Phase 3 interventional study of Gepotidacin in Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 22 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
6th of 13
97 · median 61
Started
2024
with 1 other
Phase 3
4 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 10th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Gepotidacin
  • Uncomplicated Urinary Tract Infection
  • Acute Cystitis
  • Symptom Improvement Study (SIS)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants having >=12 years of age at the time of signing the /assent and have a body weight >=40 kilograms (kg).
  • The participant has 2 or more of the following clinical signs and symptoms of acute cystitis with onset \<96 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain.
  • The participant has nitrite or pyuria (presence of 3 plus (+)/large leukocyte esterase) on a urine dipstick test from a pre-treatment clean-catch midstream urine sample.
  • The participant is capable of giving signed informed consent/assent.
  • The participant is female.

Exclusion criteria

Exclusion Criteria:

  • The participant resides in a nursing home or dependent care type-facility.
  • The participant has a >=40.0 kilogram per meter square (kg/m\^2) or a body mass index >=35.0 kg/m\^2 and is experiencing obesity-related health conditions such as uncontrolled high blood pressure or uncontrolled diabetes.
  • The participant has a history of sensitivity to the study treatment, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates her participation.
  • The participant is or has altered immune defences that may predispose the participant to a higher risk of treatment failure and/or complications.
  • The participant has any of the following:
  • Poorly controlled asthma or ; Acute severe pain, Active peptic ulcer disease; Parkinson disease; Myasthenia gravis;
  • A history of seizure disorder requiring medications for control (this does not include a history of childhood febrile seizures) Or
  • Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention.
  • The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.
  • The participant has a serious underlying disease that could be imminently life threatening, or the participant is unlikely to survive for the duration of the study period.
  • The participant has acute cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacterales (other than Escherichia coli) as the contributing pathogen.
  • The participant has symptoms known or suspected to be caused by another disease process, such as overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments or preclude complete resolution of uUTI symptoms.
  • The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (for example [e.g.], polycystic renal disease), or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract (e.g., chronic vesico-ureteral reflux, detrusor insufficiency).
  • The participant has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract.
  • The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=101.4 degree Fahrenheit (>=38 Degrees Celsius [°C]), flank pain, chills, or any other manifestations suggestive of upper UTI.
  • The participant has known anuria, oliguria, or significant impairment of renal function ( \<30 milliliters per minute (mL/min) or elevated serum creatinine as determined by the investigator).
  • The participant presents with vaginal discharge at Baseline (e.g., suspected sexually transmitted disease).
  • The participant has congenital long syndrome or known prolongation of the QTc interval.
  • The participant has uncompensated heart failure.
  • The participant has severe left ventricular hypertrophy.
  • The participant has a family history of QT prolongation or sudden death.
  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.
  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of torsade de pointes (TdP) per the www.crediblemeds.org. "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 () inhibitor or a strong P-gp inhibitor
  • The participant has a mean triplicate QTc >450 msec or a mean triplicate QTc >480 msec for participants with bundle-branch block.
  • The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
  • The participant has a known value >2 times (ULN).
  • The participant has a known value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • The participant has a current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), including symptomatic viral hepatitis or moderate-to-severe liver insufficiency ( class B or C).
  • The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry.
  • The participant plans to use any of the prohibited medications or nondrug therapies from the Baseline Visit through 7 days after the first dose of study intervention.
  • The participant has been previously enrolled in this study or has previously been treated with gepotidacin.
  • The participant has participated in a clinical trial and has received an product within 30 days or 5 half-lives, whichever is longer.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Gepotidacin

    Single Arm

    Drug: Gepotidacin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)

    Clinical Symptom improvement is defined as a decrease from Baseline in CSS (Clinical Symptom Score) total score of at least 1 point at 24 hours (±4 hours), without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

    Time frame: At 24 hours (h) (±4 h)

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Symptom Improvement

    Clinical Symptom improvement is defined as a decrease from Baseline in CSS total score of at least 1 point at each timepoint(i.e.,48 hours (±4 hours), 72 hours (±4 hours), and 96 hours (±4 hours)), without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

    Time frame: At 48 hours (h) (±4 h), 72 hours (±4 h), 96 hours (±4 h)

  2. Percentage of Participants Achieving Clinical Symptom Resolution

    Clinical Symptom resolution is defined as a decrease from Baseline to a CSS total score of 0 at each timepoint(i.e., 24 hours (±4 hours), 48 hours (±4 hours), 72 hours (±4 hours), and 96 hours (±4 hours)) without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

    Time frame: At 24 hours (±4 h), 48 hours (±4 h), 72 hours (±4 h), 96 hours (±4 h)

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AE of Special Interest (AESIs)

    Adverse Event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death,is life-threatening,required hospitalization or prolongation of existing hospitalization,resulted in disability/incapacity,is congenital anomaly/birth defect, other situations which involved medical or scientific judgment or was associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs displayed are TEAEs defined as any AE with an onset date/time on or after treatment start date/time. AESIs include cardiovascular(CV) AEs, gastrointestinal(GI) AEs, clostridioides difficile-associated diarrhea (C. difficile AEs), Acetylcholinesterase Inhibition(AchE-I). AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA). The AE data presented below is of frequency threshold-0%.

    Time frame: Up to 159 days

07

Results

Posted Feb 11, 2026

Participant flow

Participant flow — Overall Study
MilestoneGepotidacin
Started97
Completed96
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)

Clinical Symptom improvement is defined as a decrease from Baseline in CSS (Clinical Symptom Score) total score of at least 1 point at 24 hours (±4 hours), without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

Time frame:
At 24 hours (h) (±4 h)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)
Percentage of participantsGepotidacin
Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)54.4 (43.6 to 65.0)
SecondaryPercentage of Participants Achieving Clinical Symptom Improvement

Clinical Symptom improvement is defined as a decrease from Baseline in CSS total score of at least 1 point at each timepoint(i.e.,48 hours (±4 hours), 72 hours (±4 hours), and 96 hours (±4 hours)), without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

Time frame:
At 48 hours (h) (±4 h), 72 hours (±4 h), 96 hours (±4 h)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Symptom Improvement
Percentage of participantsGepotidacin
48 hours (±4 h)79.8 (69.9 to 87.6)
72 hours (±4 h)90.0 (81.9 to 95.3)
96 hours (±4 h)86.5 (77.6 to 92.8)
SecondaryPercentage of Participants Achieving Clinical Symptom Resolution

Clinical Symptom resolution is defined as a decrease from Baseline to a CSS total score of 0 at each timepoint(i.e., 24 hours (±4 hours), 48 hours (±4 hours), 72 hours (±4 hours), and 96 hours (±4 hours)) without the need for other systemic antimicrobials. CSS Score ranges from 0 to 12. Higher scores indicate a higher presence and severity of UTI symptoms.

Time frame:
At 24 hours (±4 h), 48 hours (±4 h), 72 hours (±4 h), 96 hours (±4 h)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Symptom Resolution
Percentage of participantsGepotidacin
24 hours (±4 h)3.3 (0.7 to 9.4)
48 hours (±4 h)12.4 (6.3 to 21.0)
72 hours (±4 h)32.2 (22.8 to 42.9)
96 hours (±4 h)53.9 (43.0 to 64.6)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AE of Special Interest (AESIs)

Adverse Event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death,is life-threatening,required hospitalization or prolongation of existing hospitalization,resulted in disability/incapacity,is congenital anomaly/birth defect, other situations which involved medical or scientific judgment or was associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs displayed are TEAEs defined as any AE with an onset date/time on or after treatment start date/time. AESIs include cardiovascular(CV) AEs, gastrointestinal(GI) AEs, clostridioides difficile-associated diarrhea (C. difficile AEs), Acetylcholinesterase Inhibition(AchE-I). AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA). The AE data presented below is of frequency threshold-0%.

Time frame:
Up to 159 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AE of Special Interest (AESIs)
ParticipantsGepotidacin
TEAEs27
SAEs0
AESIs23

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to 159 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gepotidacin0/97 (0%)0/97 (0%)23/97 (23.7%)
Most frequent other events
Most frequent other events
EventGepotidacin
DiarrhoeaGastrointestinal disorders16/97
FlatulenceGastrointestinal disorders6/97
DizzinessNervous system disorders5/97
Abdominal painGastrointestinal disorders4/97
HeadacheNervous system disorders3/97
Abdominal discomfortGastrointestinal disorders2/97
NauseaGastrointestinal disorders2/97

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Gepotidacin
Mean45.7 ± 16.39
Sex: Female, Male
Sex: Female, Male(Participants)Gepotidacin
Female97
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gepotidacin
Hispanic or Latino55
Not Hispanic or Latino42
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Gepotidacin
White69
Black or African American20
Asian2
American Indian or Alaska Native1
Multiple1
Not Reported2
Unknown2
08

Study locations

22 sites
  • GSK Investigational Site
    Modesto, California 95350-5365, United States
  • GSK Investigational Site
    Pasadena, California 91101-2453, United States
  • GSK Investigational Site
    San Diego, California 92120-5259, United States
  • GSK Investigational Site
    Valencia, California 91355, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32174-6302, United States
  • GSK Investigational Site
    Palm Springs, Florida 33406-7671, United States
  • GSK Investigational Site
    Palm Springs, Florida 33461, United States
  • GSK Investigational Site
    Plant City, Florida 33563-4202, United States
  • GSK Investigational Site
    Sweetwater, Florida 33172-2741, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409-3401, United States
  • GSK Investigational Site
    West New York, New Jersey 07093-2622, United States
  • GSK Investigational Site
    New York, New York 10016-7313, United States
  • GSK Investigational Site
    Dayton, Ohio 45424, United States
  • GSK Investigational Site
    Forney, Texas 75126-4174, United States
  • GSK Investigational Site
    Houston, Texas 77036, United States
  • GSK Investigational Site
    Houston, Texas 77087, United States
  • GSK Investigational Site
    Kingwood, Texas 26537, United States
  • GSK Investigational Site
    Mesquite, Texas 75149, United States
  • GSK Investigational Site
    Missouri City, Texas 77459-4756, United States
  • GSK Investigational Site
    Bountiful, Utah 84010-4943, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26501, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2025, 5 months.

Results were first posted in Feb 2026, 11 months after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 5 months is below that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 19, 2024
StartActual
Oct 2, 2024
Primary completionActual
Mar 10, 2025
CompletionActual
Mar 10, 2025
Results first posted
Feb 11, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06597344
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 2, 2024
Primary completion
Mar 10, 2025
Completion
Mar 10, 2025
Results posted
Feb 11, 2026
Last update
Feb 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion